Tryton Medical, Inc.

Tryton Medical, Inc. develops and commercializes medical devices aimed at treating coronary artery disease, specifically focusing on bifurcation lesions with innovative stenting solutions. Founded in 2003 and headquartered in Durham, US, Tryton Medical, Inc. specializes in creating devices for coronary artery interventions.

The company has undergone strategic development since its inception, culminating in 6 total deals to date. Their most recent funding round in September 2014 raised USD 20. 00 mn from investors including 3x5 Partners, Evidity Health Capital, and RiverVest Ventures Partners, marking a significant step in their funding journey. Tryton Medical specializes in the development and commercialization of advanced medical devices focused on bifurcation lesions in coronary artery disease.

Their flagship product, the Tryton Side Branch Stent, is designed to simplify treatment procedures and improve procedural and device success rates compared to provisional stenting strategies. This device addresses the specific challenges associated with treating bifurcated arteries, allowing for predictable patient outcomes. The primary end users of the Tryton Side Branch Stent are healthcare professionals, particularly interventional cardiologists, who utilize this device on patients suffering from conditions like myocardial infarction. The product is primarily marketed and sold in the United States, with additional distribution in select international markets, where it meets specific regulatory approvals for medical devices.

Tryton Medical's revenue model is primarily structured around direct sales of their medical devices to healthcare providers, hospitals, and clinics. Each transaction typically involves healthcare professionals purchasing the Tryton Side Branch Stent, which is utilized in catheterization procedures. The pricing framework for these transactions is based on the individual stent's specifications, which are sold directly to medical facilities. Additionally, the company may engage in partnerships with distributors to expand its market reach, ensuring availability in regions where the product is commercially viable.

This business model allows Tryton Medical to maintain a focused approach on surgical applications within interventional cardiology, capitalizing on the need for effective solutions in treating complex coronary artery conditions. Following their recent funding round in September 2014, which raised USD 20. 00 mn, Tryton Medical plans to use these resources to enhance their product line and expand their market presence. The company is currently developing additional products aimed at improving treatment outcomes in coronary interventions.

They are also targeting expansion into new geographical markets, specifically in Europe and Asia, by 2025, to increase their reach and accessibility of their innovative devices.